FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783200533> ?p ?o ?g. }

• W2783200533 abstract "The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies. An observational study database of patients with EBC receiving trastuzumab-containing (neo)adjuvant therapy was screened to identify those patients who did not receive cytostatic agents. Of 3935 patients, 232 (6%) were identified who received no chemotherapy, being characterized by older age, worse performance status, and/or less aggressive histology. Relapse-free survival in this cohort was 84% (95% confidence interval [CI] 78–89%) at 3 years and 80% (95% CI 74–87%) at 5 years. However, these rates were significantly worse than those in the group of patients who received chemotherapy (hazard ratio 1.49; 95% CI 1.06–2.09; P = 0.022). A similar pattern was observed for overall survival, with marginally non-significant inferiority in the group receiving no chemotherapy (hazard ratio 1.56; 95% CI 1.00–2.44; P = 0.052). Survival rates in patients receiving no chemotherapy were 93% (95% CI 88–97%) and 87% (95% CI 81–93%) at 3 and 5 years, respectively. These findings were confirmed by a propensity score analysis accounting for selection bias. Trastuzumab plus chemotherapy should remain the preferred option in all patients with HER2-positive EBC with an indication for adjuvant treatment. However, a limited proportion of patients will need an alternative treatment approach, either because of contraindications or the patient’s preference. In these selected patients, trastuzumab monotherapy, eventually combined with endocrine agents, might be a reasonable option offering favorable long-term outcomes by addressing the high-risk profile associated with HER2-positive disease." @default.
• W2783200533 created "2018-01-26" @default.
• W2783200533 creator A5010594062 @default.
• W2783200533 creator A5010710488 @default.
• W2783200533 creator A5010794657 @default.
• W2783200533 creator A5013142812 @default.
• W2783200533 creator A5027520407 @default.
• W2783200533 creator A5039265862 @default.
• W2783200533 creator A5039753601 @default.
• W2783200533 creator A5054037731 @default.
• W2783200533 creator A5071659870 @default.
• W2783200533 creator A5077954094 @default.
• W2783200533 creator A5079290836 @default.
• W2783200533 creator A5081388673 @default.
• W2783200533 creator A5081805077 @default.
• W2783200533 creator A5084585542 @default.
• W2783200533 date "2018-01-08" @default.
• W2783200533 modified "2023-10-01" @default.
• W2783200533 title "Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study" @default.
• W2783200533 cites W1519803364 @default.
• W2783200533 cites W1925211454 @default.
• W2783200533 cites W2017780448 @default.
• W2783200533 cites W2020651525 @default.
• W2783200533 cites W2036193982 @default.
• W2783200533 cites W2040935952 @default.
• W2783200533 cites W2045324973 @default.
• W2783200533 cites W2054083910 @default.
• W2783200533 cites W2083815860 @default.
• W2783200533 cites W2096496632 @default.
• W2783200533 cites W2096884232 @default.
• W2783200533 cites W2097541112 @default.
• W2783200533 cites W2098775844 @default.
• W2783200533 cites W2100023433 @default.
• W2783200533 cites W2113450161 @default.
• W2783200533 cites W2124845354 @default.
• W2783200533 cites W2138977450 @default.
• W2783200533 cites W2140055441 @default.
• W2783200533 cites W2144168223 @default.
• W2783200533 cites W2144506947 @default.
• W2783200533 cites W2154343503 @default.
• W2783200533 cites W2159459001 @default.
• W2783200533 cites W2166034342 @default.
• W2783200533 cites W2173858545 @default.
• W2783200533 cites W2586164340 @default.
• W2783200533 doi "https://doi.org/10.1186/s12885-017-3857-5" @default.
• W2783200533 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5759796" @default.
• W2783200533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29310623" @default.
• W2783200533 hasPublicationYear "2018" @default.
• W2783200533 type Work @default.
• W2783200533 sameAs 2783200533 @default.
• W2783200533 citedByCount "14" @default.
• W2783200533 countsByYear W27832005332018 @default.
• W2783200533 countsByYear W27832005332019 @default.
• W2783200533 countsByYear W27832005332020 @default.
• W2783200533 countsByYear W27832005332021 @default.
• W2783200533 countsByYear W27832005332022 @default.
• W2783200533 countsByYear W27832005332023 @default.
• W2783200533 crossrefType "journal-article" @default.
• W2783200533 hasAuthorship W2783200533A5010594062 @default.
• W2783200533 hasAuthorship W2783200533A5010710488 @default.
• W2783200533 hasAuthorship W2783200533A5010794657 @default.
• W2783200533 hasAuthorship W2783200533A5013142812 @default.
• W2783200533 hasAuthorship W2783200533A5027520407 @default.
• W2783200533 hasAuthorship W2783200533A5039265862 @default.
• W2783200533 hasAuthorship W2783200533A5039753601 @default.
• W2783200533 hasAuthorship W2783200533A5054037731 @default.
• W2783200533 hasAuthorship W2783200533A5071659870 @default.
• W2783200533 hasAuthorship W2783200533A5077954094 @default.
• W2783200533 hasAuthorship W2783200533A5079290836 @default.
• W2783200533 hasAuthorship W2783200533A5081388673 @default.
• W2783200533 hasAuthorship W2783200533A5081805077 @default.
• W2783200533 hasAuthorship W2783200533A5084585542 @default.
• W2783200533 hasBestOaLocation W27832005331 @default.
• W2783200533 hasConcept C121608353 @default.
• W2783200533 hasConcept C126322002 @default.
• W2783200533 hasConcept C143998085 @default.
• W2783200533 hasConcept C17923572 @default.
• W2783200533 hasConcept C207103383 @default.
• W2783200533 hasConcept C2776694085 @default.
• W2783200533 hasConcept C2779786085 @default.
• W2783200533 hasConcept C2780140570 @default.
• W2783200533 hasConcept C44249647 @default.
• W2783200533 hasConcept C530470458 @default.
• W2783200533 hasConcept C71924100 @default.
• W2783200533 hasConceptScore W2783200533C121608353 @default.
• W2783200533 hasConceptScore W2783200533C126322002 @default.
• W2783200533 hasConceptScore W2783200533C143998085 @default.
• W2783200533 hasConceptScore W2783200533C17923572 @default.
• W2783200533 hasConceptScore W2783200533C207103383 @default.
• W2783200533 hasConceptScore W2783200533C2776694085 @default.
• W2783200533 hasConceptScore W2783200533C2779786085 @default.
• W2783200533 hasConceptScore W2783200533C2780140570 @default.
• W2783200533 hasConceptScore W2783200533C44249647 @default.
• W2783200533 hasConceptScore W2783200533C530470458 @default.
• W2783200533 hasConceptScore W2783200533C71924100 @default.
• W2783200533 hasIssue "1" @default.
• W2783200533 hasLocation W27832005331 @default.
• W2783200533 hasLocation W27832005332 @default.
• W2783200533 hasLocation W27832005333 @default.
• W2783200533 hasLocation W27832005334 @default.

• next